

## CLAIMS

What is claimed is:

1. A method of treating cardiovascular disease in a subject having cardiovascular disease, the method comprising administering to the subject a therapeutically effective amount of an antagonist, wherein the antagonist is selected from the group consisting of an IL-17 antagonist, IL-18 antagonist, 4-1BB antagonist, CD30 antagonist and an OX40 antagonist.
2. The method of Claim 1, wherein the IL-17 antagonist is a soluble IL-17 receptor.
3. The method of Claim 2, wherein the soluble IL-17 receptor is a fusion protein.
4. The method of Claim 1, wherein the IL-17 antagonist is an antibody.
5. The method of Claim 4, wherein the antibody specifically binds the IL-17 receptor.
6. The method of Claim 4, wherein the antibody specifically binds IL-17.
7. The method of Claim 4, wherein the antibody is a humanized antibody.
8. The method of Claim 4, wherein the antibody is a single-chain antibody.
9. The method of Claim 1, wherein the IL-17 antagonist is administered one or more times per week.
10. The method of Claim 1, wherein the IL-17 antagonist is administered by subcutaneous injection.
11. The method of Claim 1, wherein the IL-17 antagonist is administered in combination with one or more compounds selected from the group consisting of non-steroidal anti-inflammatory drugs; analgesics; systemic steroids; antagonists of inflammatory cytokines; anti-inflammatory cytokines; chemotherapeutics; lipid-lowering drugs; blood pressure-regulating drugs; angiotensin-converting enzyme inhibitors and/or peroxisome proliferator-activated receptor ligands.